Importantly, we found that vemurafenib therapy substantially down-regulated nuclear protein levels of cyclin B2, from about 30% of tumor cells in the vehicle-treated tumors to about 2% in vemurafenib-treated tumors (Figure 2F, Supplementary information). This evidence concerns the gene CCNB2 and neoplasm.